Claims for Patent: 10,369,196

Summary for Patent: 10,369,196

Title:	Compositions and methods for treating glioblastoma GBM
Abstract:	Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
Inventor(s):	Cohen; Yael (Kiryat-Ono, IL), Bangio; Livnat (Petach-Tikva, IL), Brenner; Andrew J. (Boerne, TX), Breitbart; Eyal (Hashmonaim, IL)
Assignee:	Vascular Biogenics Ltd. (Or Yehuda, IL)
Application Number:	13/826,303
Patent Claims:	1. A method of treating a malignant glioma in a subject in need thereof, the method comprising administering directly into the malignant glioma or intravenously to the subject a therapeutically effective amount of a non-replicating adenovirus serotype 5 vector (Ad5), wherein said adenoviral vector comprises: (i) a first nucleotide sequence comprising the nucleotide sequence of the extracellular region of TNFR1 as set forth in SEQ ID NO:2 fused to the trans-membrane and intracellular regions of Fas as set forth in SEQ ID NO:3 encoding a Fas-chimera (Fas-c); and (ii) a second nucleotide sequence of an endothelial cell-specific promoter comprising the nucleotide sequence as set forth in SEQ ID NO:6, or the complementary sequence thereof, wherein said second nucleotide sequence is operably linked to and is upstream of said first nucleotide sequence for expression of said Fas-chimera in endothelial cells, and wherein growth of the malignant glioma is inhibited. 2. The method of claim 1, wherein said promoter comprises at least two copies of the nucleotide sequence as set forth in SEQ ID NO: 6, or the complementary sequence thereof. 3. The method of claim 1, wherein said promoter further comprises the nucleotide sequence as set forth in SEQ ID NO: 8, or the complementary sequence thereof. 4. The method of claim 1, wherein said promoter comprises the nucleotide sequence as set forth in SEQ ID NO: 7, or a complementary sequence thereof. 5. The method of claim 1, wherein said promoter further comprises the hypoxia response element (HRE) as set forth in SEQ ID NO: 5. 6. The method of claim 1, wherein the malignant glioma is selected from the group consisting of glioblastoma, astrocytoma, oligodendroglioma, ependymoma, and juvenile pilocystic astrocytoma. 7. The method of claim 1, wherein the therapeutically effective amount of said adenoviral vector is 10.sup.13 virus particles. 8. The method of claim 1, wherein said administering comprises intravenous administration. 9. The method of claim 1, wherein said administering is in at least two doses of said adenoviral vector. 10. The method of claim 1, wherein said administering is at least three doses of said adenoviral vector. 11. The method of claim 1, wherein the adenoviral vector is administered as a single unit dose. 12. The method of claim 1, further comprising administering to the subject an anti-cancer drug. 13. The method of claim 12, wherein said anti-cancer drug is bevacizumab. 14. The method of claim 1, further comprising administering a therapy selected from the group consisting of chemotherapy, radiotherapy, phototherapy, photodynamic therapy, surgery, nutritional therapy, ablative therapy, brachiotherapy, proton beam therapy, immunotherapy, cellular therapy and photon beam radiosurgical therapy. 15. The method of claim 14, wherein said therapy is immunotherapy. 16. The method of claim 1, wherein said administering comprises intravenous administration, and wherein the malignant glioma is a glioblastoma. 17. The method of claim 16, wherein the therapeutically effective amount of said adenoviral vector is 10.sup.13 virus particles.

Details for Patent 10,369,196

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-08-22